Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International Inc    BAX

News SummaryMost relevantAll newsSector newsTweets 

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
12/10/2012 | 03:34pm CET
    By Saabira Chaudhuri 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
01/18 BAXTER INTERNATIONAL : Spectrum Health Recognized for Excellence in Community Se..
01/18 BAXTER INTERNATIONAL : Program Brings More Information, Treatment Choice in Afri..
01/14 BAXTER INTERNATIONAL : Pure Financial Advisors Boosts Position by $343,366
01/14 BAXTER INTERNATIONAL : unit to pay $18 million over alleged drug manufacturing v..
01/09 BAXTER INTERNATIONAL INC. : to Host Fourth Quarter 2016 Financial Results Confer..
01/09 BAXTER INTERNATIONAL : New Data Show U.S. Hospital Readmissions are 54 Percent H..
01/06 BAXTER INTERNATIONAL INC. : to Host Fourth Quarter 2016 Financial Results Confer..
2016 BAXTER INTERNATIONAL : Patent Issued for Method and System for Alerting as to Po..
2016 BAXTER INTERNATIONAL : Patent Issued for Method and Apparatus for Removing Air f..
2016 CLARIS LIFESCIENCES : sells injectables biz to Baxter for Rs 4,200 crore
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
01/17DJLUXOTTICA FOUNDER : A Lifetime of Deals -- WSJ
01/17DJLUXOTTICA : Merger to Create Eyewear Giant -- WSJ
01/17DJWHAT'S NEWS : Business & Finance -- WSJ
01/16 ESSILOR INTL : Luxottica's merger helps Del Vecchio manage family risks
01/16DJLUXOTTICA : Another Big Splash by Italy's Eyewear King
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
01/18 MERGERS AND ACQUISITIONS IN 2016 : Pause For Breath In A Shifting Market
01/09 Dripping For Fun And Profit
01/08 BECTON, DICKINSON : Does This Dividend Aristocrat Measure Up To Its Peers?
01/03 DIVIDEND GROWTH 50 : Income Increased But Income Growth Was Stunted - Part 2
2016 Stryker Poised For Long-Term Gains
Financials ($)
Sales 2016 10 168 M
EBIT 2016 1 336 M
Net income 2016 2 017 M
Debt 2016 220 M
Yield 2016 1,08%
P/E ratio 2016 4,86
P/E ratio 2017 24,41
EV / Sales 2016 2,52x
EV / Sales 2017 2,47x
Capitalization 25 439 M
More Financials
Duration : Period :
Baxter International Inc Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Full-screen chart
Technical analysis trends BAXTER INTERNATIO...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 16
Average target price 52,8 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC6.23%103 898
C R BARD INC4.51%17 263
TERUMO CORP-3.01%13 900
More Results